G
Grace Therapeutics, Inc. (GRCE)
NCM – Real Time Price. Currency in USD
2.33
-0.02 (-0.85%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
2.33
-0.02 (-0.85%)
At close: May 12, 2026, 4:00 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 14.96 | 6.05 | 10 | |
| Quick ratio | 14.96 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | -124K | -11K | -7K | -7K |
| Operating Income | -16M | -18M | -11M | -17M | -11M |
| Net Income | -10M | -42M | -13M | -10M | -6M |
| EBITDA | -16M | -18M | -11M | -17M | -11M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | -309.09 | 1.0 |
| Next quarter | N/A | 28.57 | 5.5 |
| Current year | N/A | -4.43 | 1.0 |
| Next year | N/A | 24.85 | 5.5 |
| Weighted average score | 3.3 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -146.79 | -133.32 | 31.26 | 5.5 |
| Y/Y | 999 | 44.28 | 61.11 | 44.35 | 10 |
| 3y average | 999 | -78.93 | -44.67 | 3.13 | 4.0 |
| 5y average | 779.2 | -32.76 | -2.1 | 5.55 | 4.3 |
| Weighted average score | 6.0 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Cash reserves $18.7M barely cover the upcoming debt maturities $0.0
Total current assets $19.2M exceed Total current liabilities $1.3M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is near the industry average, reflecting balanced leverage
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$2.2M limits the company's ability to reinvest or pay down debt